Meeting
2018 Gastrointestinal Cancers Symposium
A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.
Authors
Haeseong Park
Washington University School of Medicine in St. Louis, St. Louis, MO
Haeseong Park , Andrea Wang-Gillam , Rama Suresh , Caron E. Rigden , Manik A. Amin , Benjamin R. Tan Jr., Katrina Pedersen , Kian-Huat Lim , Nikolaos Trikalinos , Katherine Navo , Ashley Morton , Lindsey Schrumpf , Samantha Marquez , Kathryn Trinkaus , A. Craig Lockhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01928290
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 89)
DOI
10.1200/JCO.2018.36.4_suppl.89
Abstract #
89
Poster Bd #
G17
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.
First Author: Ramon Jin
Poster
2015 Gastrointestinal Cancers Symposium
FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).
First Author: Albert C. Lockhart
Poster
2017 ASCO Annual Meeting
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: Petrarca—A phase II trial of the German AIO.
First Author: Ralf Hofheinz
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023).
First Author: Rongbo Lin